Immunoglobulins

Hizentra may treat patients with chronic inflammatory demyelinating polyneuropathy.

Real-world dose adjustments occurred in patients with primary immunodeficiency who switched from intravenous immunoglobulin to subcutaneous immunoglobulin 20%, with resulting implications for payers, patients, and plasma collection and supply.

The first report of long-term (3-year) stabilization of Alzheimer's disease symptoms with IVIG, including no decline on measures of cognition, memory, daily functioning and mood, was recently reported at the Alzheimer's Association International Conference 2012 in Vancouver.

This home delivery pharmacy focuses in intravenous immune globulin programs to improve care and outcomes for patients.

When patients have immunodeficiency conditions that require immunoglobulin therapy (IVIG), clinicians must consider carefully which IVIG product will have the fewest adverse effects and the highest level of efficacy.